1. Home
  2. IBRX vs ATS Comparison

IBRX vs ATS Comparison

Compare IBRX & ATS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IBRX
  • ATS
  • Stock Information
  • Founded
  • IBRX 2014
  • ATS 1978
  • Country
  • IBRX United States
  • ATS Canada
  • Employees
  • IBRX N/A
  • ATS N/A
  • Industry
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • ATS
  • Sector
  • IBRX Health Care
  • ATS
  • Exchange
  • IBRX Nasdaq
  • ATS Nasdaq
  • Market Cap
  • IBRX 2.3B
  • ATS 2.7B
  • IPO Year
  • IBRX N/A
  • ATS 2023
  • Fundamental
  • Price
  • IBRX $2.53
  • ATS $26.47
  • Analyst Decision
  • IBRX Strong Buy
  • ATS
  • Analyst Count
  • IBRX 6
  • ATS 0
  • Target Price
  • IBRX $9.83
  • ATS N/A
  • AVG Volume (30 Days)
  • IBRX 10.3M
  • ATS 98.9K
  • Earning Date
  • IBRX 11-11-2025
  • ATS 08-07-2025
  • Dividend Yield
  • IBRX N/A
  • ATS N/A
  • EPS Growth
  • IBRX N/A
  • ATS N/A
  • EPS
  • IBRX N/A
  • ATS N/A
  • Revenue
  • IBRX $56,600,000.00
  • ATS $1,886,061,785.00
  • Revenue This Year
  • IBRX $629.94
  • ATS $17.99
  • Revenue Next Year
  • IBRX $109.91
  • ATS $5.49
  • P/E Ratio
  • IBRX N/A
  • ATS N/A
  • Revenue Growth
  • IBRX 4227.22
  • ATS N/A
  • 52 Week Low
  • IBRX $1.83
  • ATS $20.90
  • 52 Week High
  • IBRX $7.48
  • ATS $33.13
  • Technical
  • Relative Strength Index (RSI)
  • IBRX 47.77
  • ATS 44.03
  • Support Level
  • IBRX $2.42
  • ATS $26.08
  • Resistance Level
  • IBRX $2.75
  • ATS $27.18
  • Average True Range (ATR)
  • IBRX 0.13
  • ATS 0.74
  • MACD
  • IBRX -0.01
  • ATS 0.02
  • Stochastic Oscillator
  • IBRX 22.88
  • ATS 33.78

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About ATS ATS Corporation

ATS Corp is a Canada-based company that provides automation systems. The company designs and builds customized automated manufacturing and testing systems for customers, and provides pre- and post-automation services. The company's products comprise conveyor systems, automated electrified monorails, tray handlers, laser systems, and other hardware and software products. The company also provides pre-automation solutions, including strategic direction and planning services, as well as aftermarket support. The company's clients come from the life sciences, food and beverage transportation, consumer products and electronics, and energy sectors. The company generates the majority of its sales from the North American and European markets.

Share on Social Networks: